Company: CERO
Filing Date: 2025-10-30
Form Type: 424B3
Source: 0001213900-25-104117
Chunk: 3

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-10-30
Form: 424B3
Chunk 3
---
 stock or that the shares of common stock will be admitted
for trading on the OTC Markets. The OTC Markets also are a less liquid market than Nasdaq, which may have a material adverse effect on
the trading price and volume for the common stock. The Company is also considering listing alternatives, including applying to list its
shares of common stock on another securities exchange.

The Company currently plans to continue its clinical trials, including
the dosing of patients in such trials. As described previously by CERO, evidence gathered for CER-1236 in the first three AML cancer patients
dosed at the initial low dose showed rapid cell expansion of CER-1236 in these patients, along with observation of no toxicity.
Moreover the second patient, infused with three of the low doses in succession, continues on trial. The company believes these early
stage observations support continued clinical development of CER-1236 at the planned higher dose, and is progressing on this plan. The
Company is currently reviewing its cash resources and potential financing alternatives to fund its continued operations. The Company can
provide no assurance that it will be able to obtain such financing on acceptable terms, or at all.

Item 8.01. Other Events.

On October 29, 2025,
the Company issued a press release announcing the Hearings Panel’s determination. Such press release is filed as Exhibit 99.1 hereto
and is hereby incorporated by reference herein.

Item 9.01 Exhibits.

(d) Exhibits.

| Exhibit 
 Number  
 99.1    |     | Description                                                                  
 Press Release dated October 29, 2025                                         |
|:--------|:----|:-----------------------------------------------------------------------------|
| 104     |     | Cover Page Interactive Data File (embedded within the Inline XBRL document). |

<div align='center'>1

SIGNATURE</div>

Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

| CERO THERAPEUTICS HOLDINGS, INC. |                         |
| By:                              | /s/ Chris Ehrlich       |
| Name:                            | Chris Ehrlich           |
| Title:                           | Chief Executive Officer |

Dated: October 29, 2025

<div align='center'>2</div>